Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Repurposing Etalocib suppresses multidrug-resistant staphylococcus aureus

ABSTRACT: Staphylococcus aureus (S. aureus) is common gram-positive bacteria that prominently causes community acquired infection (CAI) and hospital acquired infection (HAI) makes it a versatile and dangerous, Antibiotic resistance and the long - term nature of new drug research and development have forced the search for new research methods of antibacterial drugs. Drug repositioning is a new research approach for antibacterial drugs. Etalocib is found through screening the compound library, and its antibacterial activity is studied and the antibacterial mechanism is explored.

ORGANISM(S): Staphylococcus Aureus

SUBMITTER: Zewen Wen

PROVIDER: PXD057734 | iProX | Mon Nov 11 00:00:00 GMT 2024

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

GSK2018682 against Staphylococcus aureus proteome

Project description:Staphylococcus aureus (S, aureus) is common gram-positive bacteria that prominently causes community acquired infection (CAl) and hospital acquired infection (HAl) makes it a versatile and dangerous, Antibiotic resistance and the long - term nature of new drug research and development have forced the search for new research methods of antibacterial drugs. Drug repositioning is a new research approach for antibacterial drugs. GSK2018682 is found through screening the compound library, and its antibacterial activity is studied and the antibacterial mechanism is explored.

2025-08-01 | PXD066899 |

Crizotinib, Tyrosine Kinase Inhibitors, Create an Antibacterial Active against Gram-positive Bacteria by Targeting the CTP Synthetase PyrG

Project description:Abstract The infection of drug resistant bacteria seriously threats to public health, which makes it more urgent to find novel antibacterial compounds. Compared with traditional development approaches, drug repurposing provides a faster and more effective strategy to find new antimicrobial agents. Here, we screened an FDA-approved small-molecule library upon S. aureus, and identified crizotinib as an antimicrobial agent. We confirmed the antibacterial activities of crizotinib in vitro and in vivo by MIC, growth curve, SEM and mice experiment. At the same time, crizotinib also showed low tendency to develop resistance. Mechanistically, quantitative proteomics, bioinformatics analyses, qRT-PCR and flow cytometry biochemical validation experience confirmed that crizotinib exerted its antibacterial effects by interfering pyrimidine metabolism and disrupting DNA synthesis eventually. Furthermore, our data from drug affinity responsive target stability, bio-layer interferometry and a series of functional assays demonstrated that crizotinib could target PyrG directly in pyrimidine metabolism pathway. Taken together, our results indicated that crizotinib could be a potential antimicrobial agent to treat Gram-positive bacterial infections in the future.

2022-03-10 | PXD029546 | Pride

An optimized antibiotic from rhizobacteria against multidrug-resistant Gram-positive pathogens

Project description:The rapid rise of antibiotic resistance and the urgent need for new antibiotics call for the unique skeleton of compounds with different mechanisms of action. Microbial natural products dominate the preferred chemical scaffolds for antibiotic discovery. A plant-microbial antibiotic is an appealing origin yet underexplored due to a dearth of comprehensive studies of antibacterial activity and structural characteristics. In this study, phloroglucinol derived isolated from the plant-root-associated bacterium Pseudomonas fluorescens was modified for structure–activity relationship study. 2,4-diproylphloroglucinol (DPPG) displayed bactericidal activity against a wide range of Gram-positive bacteria including multidrug-resistant pathogens. Interestingly, the bactericidal mechanism study exhibits that DPPG binds to type II NADH dehydrogenases (NDH-2) in the respiratory chain and disrupts the proton-motive force of S. aureus. We validated the efficacy of DPPG in vivo through mice models associated with infection or contamination. Our finding provides a novel antibiotic to treat S. aureus- associated infections and a potential target for antibiotic design and study.

2025-02-15 | PXD040775 | Pride

Transcriptional responses of CDCA treated Staphylococcus aureus cells

Project description:Analysis of Staphylococcus aureus treated by CDCA. Staphylococcus aureus cells are evaluated with RNA-seq to understand the genes affected by this antibacterial agent. Our results provide new vision on the mode of action by CDCA.

2022-10-15 | GSE193011 | GEO

Transcriptional responses of Tanreqing treated Staphylococcus aureus cells

Project description:Analysis of Staphylococcus aureus treated by Tanreqing. Staphylococcus aureus cells are evaluated with RNA-seq to understand the genes affected by this antibacterial agent. Our results provide new vision on the mode of action by Tanreqing.

2021-06-07 | GSE162107 | GEO

Small Polar Hits against S. aureus: Screening, Initial Hit Optimization, and Metabolomic Studies

Project description:The global prevalence of antibacterial resistance requires new antibacterial drugs with novel chemical scaffolds and modes of action. It is also vital to design compounds with optimal physicochemical properties to permeate the bacterial cell envelope. We described an approach of combining and integrating whole cell screening and metabolomics into early antibacterial drug discovery using a library of small polar compounds. Whole cell screening of a diverse library of small polar compounds against Staphylococcus aureus gave compound 2. Hit expansion was carried out to determine structure-activity relationships. A selection of compounds from this series, together with other screened active compounds, was subjected to an initial metabolomics study to provide a metabolic fingerprint of the mode of action. It was found that compound 2 and its analogues have a different mode of action from some of the known antibacterial compounds tested. This early study highlighted the potential of whole cell screening and metabolomics in early antibacterial drug discovery. Future works will require improving potency and performing orthogonal studies to confirm the modes of action.

2021-11-04 | MTBLS788 | MetaboLights

Repurposing cinacalcet suppresses multi-drug resistant Staphylococcus aureus by disruption of cell membrane and inhibits biofilm by targeting IcaR

Project description:Multi-drug resistant Staphylococcus aureus (S. aureus) infections continously threaten public health. The rapid escalation in morbidity and mortality rates associated with methicillin-resistant S. aureus (MRSA) infections necessitates the urgent development of novel antimicrobial agents. Our study reveals that the FDA-approved drug cinacalcet (CNA) effectively functions as an antibacterial and anti-biofilm agent against S. aureus without detectable resistance. It evidently improved survival rate of mice infected with clinical multi-resistant S. aureus in a pneumonia model. Subsequent proteomic and biochemical experiments suggest that the primary antibacterial mechanism involves membrane structure disruption, ATP content reduction, and reactive oxygen species (ROS) production. Concurrently, LiP-SMap combined with biochemical validation indicates that CNA inhibits biofilm formation by targeting IcaR, a negative regulator of icaADBC, thereby enhancing its binding capacity to the ica operator DNA and subsequently suppressing extracellular polysaccharide formation. Importantly, compared to vancomycin, CNA demonstrates stronger biofilm bacterial clearance in a mouse thigh infection model. Collectively, our findings propose that CNA can be repurposed as a potential therapeutic agent for treating multidrug-resistant S. aureus infections and their associated biofilms.

2024-02-07 | PXD041266 | Pride

The Antibacterial effect and molecular mechanism of paeonol on Aeromonas hydrophila

Project description:The abuse of antibiotics leads to the increasingly serious problem of bacterial drug resistance, which makes an urgent tendency to find promising alternative drugs for antibiotics. Paeonol, as a natural plant active ingredient, exhibits good antibacterial potential. To further study the molecular mechanism of the antibacterial effect of paeonol, the potential antibacterial mechanism of paeonol was analyzed by using proteomics and bioinformatics with Aeromonas hydrophila as the main experimental object.

2025-01-07 | PXD059529 |

IgE Effector Mechanisms, in Concert with Mast Cells, Contribute to Acquired Host Defense against Staphylococcus aureus

Project description:Best known for their roles in allergic diseases, the physiologic function of immunoglobulin E (IgE) and mast cells (the so-called allergy module of immunity) has been enigmatic. Recent evidence shows that allergic reactions can help to protect against the toxicity of venoms. As bacteria are a potent alternative source of toxins, we assessed the potential role of the allergy module in antibacterial host defense. We observed that the immune response against S. aureus skin infection includes specific IgEs and substantially improves systemic host defense against secondary S. aureus infections in mice. This acquired protection depends on functional IgE effector mechanisms and mast cells. Our results reveal the powerful antibacterial potential of the allergy module and therefore a novel physiologic function of IgEs and mast cells.

2020-09-10 | PXD019107 | Pride

Phenotype and expression profile analysis of Staphylococcus aureus biofilms and planktonic cells in response to Licochalcone A

Project description:Staphylococcus aureus (S. aureus) is one of the most important pathogens in humans and animals. The formation of S. aureus biofilm is considered an important mechanism of antimicrobial resistance. Therefore, finding effective drugs against the biofilm produced by S. aureus has been a high priority. Licochalcone A, a natural plant product, was reported to have antibacterial activities and showed good activity against all 21 tested strains of S. aureus biofilm and planktonic cells. To detect the possible molecular mechanism of Licochalcone A against S. aureus biofillm or planktonic cells, Affymetrix GeneChips were used to determine the global comparative transcription of S. aureus biofilm and planktonic cells triggered by treatment with sub-bactericidal and sub-inhibitory concentrations of Licochalcone A, respectively.

2014-07-01 | GSE58938 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data